Habitrol Nicotine Patch Three-Year Exclusivity Sought By Novartis
This article was originally published in The Tan Sheet
Executive Summary
A shortened duration of use and a new, essential clinical investigation supporting OTC use of the Habitrol transdermal nicotine patch merits the granting of three years of marketing exclusivity, Novartis Consumer Health maintains.